FDA authorizes COVID-19 antibody test’s emergency use
The Food and Drug Administration Oct. 12 issued an emergency use authorization for Abbott Laboratories’ AdviseDx SARS-CoV-2 IgM (Immunoglobulin M) lab-based serology test.
Abbott said the test, which is used on its ARCHITECT and Alinity platforms, has demonstrated high reliability in its research and external virology laboratory studies, with 99.56% specificity and 95% sensitivity for patients tested 15 days after symptom onset.
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…